[1]
|
R. W. Veltri, M. C. Miller, G. J. O’dowd and A. W. Partin, “Impact of Age on Total and Complexed ProstateSpecific Antigen Cut offs in a Contemporary Referral Series of Men with Prostate Cancer,” Urology, Vol. 60, No. 4, 2002, pp. 47-52. doi:10.1016/S0090-4295(02)01695-3
|
[2]
|
H. Lilja, D. Ulmert and A. J. Vickers, “Prostate-Specific Antigen and Prostate Cancer: Prediction, Detection and Monitoring,” Nature Reviews: Cancer, Vol. 8, No. 4, 2008, pp. 268-278. doi:10.1038/nrc2351
|
[3]
|
S. M. Falzarano and C. Magi-Galluzzi, “Prostate Cancer Staging and Grading at Radical Prostatectomy over Time,” Advances in Anatomic Pathology, Vol. 18, No. 2, 2011, pp. 159-164. doi:10.1097/PAP.0b013e31820cb506
|
[4]
|
J. E. Oesterling, S. J. Jacobsen, G. G. Klee, et al., “Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for Their Concentrations and Ratios,” The Journal of Urology, Vol. 154, No. 3, 1995, pp. 1090-1095.
doi:10.1016/S0022-5347(01)66984-2
|
[5]
|
S. F. Shariat, A. Semjonow, H. Lilja, et al., “Tumour Markers in Prostate Cancer I: Blood-Based Markers,” Acta Oncologica, Vol. 50, No. S1, 2011, pp. 61-75.
doi:10.3109/0284186X.2010.542174
|
[6]
|
R. Morgan, A. Boxall, A. Bhatt, et al., “Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer,” Clinical Cancer Research, Vol. 17, No. 5, 2011, pp. 1090-1098.
doi:10.1158/1078-0432.CCR-10-2410
|
[7]
|
H. Pandha, K. D. Sorensen, T. F. Orntoft, et al., “Urinary Engrailed-2 (EN2) Levels Predict Tumour Volume in Men Undergoing Radical Prostatectomy for Prostate Cancer,” BJU International, Vol. 110, No. 6, 2012, pp. E287-E292. doi:10.1111/j.1464-410X.2012.11208.x
|
[8]
|
J. I. Epstein, P. C. Walsh and H. B. Carter, “Dedifferentiation of Prostate Cancer Grade with Time in Men Followed Expectantly for Stage T1c Disease,” The Journal of Urology, Vol. 166, No. 5, 2011, pp. 1688-1691.
|
[9]
|
T. Wolters, M. J. Roobol, P. J. van Leeuwen, et al., “A Critical Analysis of the Tumour Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial,” The Journal of Urology, Vol. 185, No. 1, 2011, pp. 121-125.
doi:10.1016/j.juro.2010.08.082
|
[10]
|
H. U. Ahmed, M. Arya, A. Freeman, et al., “Do LowGrade and Low-Volume Prostate Cancers Bear the Hallmarks of Malignancy?” The Lancet Oncology, Vol. 13, No. 11, 2012, pp. e509-e517.
|
[11]
|
L. Klotz, “Active Surveillance for Prostate Cancer: A Review,” Current Urology Reports, Vol. 11, No. 3, 2010, pp. 165-171. doi:10.1007/s11934-010-0110-z
|
[12]
|
L. Salomon, O. Levrel, A. G. Anastasiadis, et al., “Prognostic Significance of Tumour Volume after Radical Prostatectomy: A Multivariate Analysis of Pathological Prognostic Factors,” European Urology, Vol. 43, No. 1, 2003, pp. 39-44. doi:10.1016/S0302-2838(02)00493-1
|
[13]
|
J. R. Prensner, M. A. Rubin, J. T. Wei, et al., “Beyond PSA: The Next Generation of Prostate Cancer Biomarkers,” Science Translational Medicine, Vol. 4, No. 127, 2012, Article ID: 127rv3.
|
[14]
|
G. Ploussard, X. Durand, E. Xylinas, et al., “Prostate Cancer Antigen 3 Score Accurately Predicts Tumour Volume and Might Help in Selecting Prostate Cancer Patients for Active Surveillance,” European Urology, Vol. 59, No. 3, 2011, pp. 422-429. doi:10.1016/j.eururo.2010.11.044
|
[15]
|
H. Nakanishi, J. Groskopf, H. A. Fritsche, et al., “PCA3 Molecular Urine Assay Correlates with Prostate Cancer Tumor Volume: Implication in Selecting Candidates for Active Surveillance,” The Journal of Urology, Vol. 179 No. 5, 2008, pp. 1804-1809.
doi:10.1016/j.juro.2008.01.013
|
[16]
|
E. J. Whitman, J. Groskopf, A. Ali, et al., “PCA3 Score before Radical Prostatectomy Predicts Extracapsular Extension and Tumor Volume,” The Journal of Urology, Vol. 180, No. 5, 2008, pp. 1975-1979.
doi:10.1016/j.juro.2008.07.060
|
[17]
|
M. P. van Gils, D. Hessels, C. A. Hulsbergen-van de Kaa, et al., “Detailed Analysis of Histopathological Parameters in Radical Prostatectomy Specimens and PCA3 Urine Test Results,” The Prostate, Vol. 68, No. 11, 2008, pp. 1215-1222. doi:10.1002/pros.20781
|
[18]
|
D. Hessels, M. P. van Gils, O. van Hooij, et al., “Predictive Value of PCA3 in Urinary Sediments in Determining Clinico-Pathological Characteristics of Prostate Cancer,” The Prostate, Vol. 70, No. 1, 2010, pp. 10-16.
doi:10.1002/pros.21032
|
[19]
|
M. Auprich, F. K. Chun, J. F. Ward, et al., “Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging,” European Urology, Vol. 59, No. 1, 2011, pp. 96-105.
doi:10.1016/j.eururo.2010.10.024
|
[20]
|
M. W. Kattan, “Do We Need More Nomograms for Predicting Outcomes in Patients with Prostate Cancer?” Nature Reviews Urology, Vol. 5, No. 7, 2008, pp. 366-367.
doi:10.1038/ncpuro1128
|